Welcome to BioSeeker Group!

RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012

Additional Information

Published Date Feb 21, 2012
Format Software Application
Publisher BioSeeker Group
Product Line View All Available Drug Pipeline Update Reports

Availability: In stock

€1,499.00

Quick Overview

BioSeeker Group have identified 164 companies plus partners who are today developing 192 RANKL pathway targeting drugs in 643 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 104 drugs where development has been ceased.
Request free sample pages from RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012

Executive Summary

BioSeeker Group have identified 164 companies plus partners who are today developing 192 RANKL pathway targeting drugs in 643 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 104 drugs where development has been ceased.

For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field, we offer the Drug Pipeline update series.

You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug.

Buying the RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012 will mean you have this important data at your fingertips and ensure that you can:

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc. and track them by their products.
* Jump start competitive drug intelligence operations
* Benchmark your own development against world wide data
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/outlicensing strategy work


Some facts about RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012

Receptor activator of nuclear factor-kappa B ligand (RANKL) is a member of tumor necrosis factor (TNF) superfamily. It binds to Receptor activator of NF-kB (RANK) and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C (PKC), Ca2+/Calcineurin/nuclear factor of activated T cells (NFAT) and phosphatidyl 3-kinase (PI3K). The RANKL-RANK signaling system is negatively regulated by a decoy receptor known as Osteoprotegerin.
There are today 164 companies plus partners developing 192 RANKL pathway targeting drugs in 643 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 104 drugs. Rankl Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 104 different targets. These targets are further categorized on in the software application by 29 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath.


Details from RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012 at a glance

This short overview shows actual findings from the RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012 report.

Investigators Includes more than 164 principal investigators plus their collaborators. There is direct access from inside the application to web pages of all principal investigators.

Note: You are able to sort and find drugs according to investigators and partners from drop-down menus in the application. You may also sort and find drugs according to country of investigator.
Drug name & Synonyms Lists commercial, generic and code names for drugs.
Developmental stage This Drug Pipeline Update contains 192 RANKL pathway targeting drugs in development, which have a total of 643 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 12
Registered# 1
Pre-registration# 1
Phase III# 20
Phase II# 56
Phase I# 78
Preclinical# 119
No Data# 1
Suspended# 1
Ceased# 104

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included RANKL pathway targeting drugs are also in development for 116 other indications, where of 66 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets Identified drugs are linked to more than 104 different targets, divided into 29 classifications of molecular function:
- Catalytic activity
- Chaperone activity
- Cysteine-type peptidase activity
- Cytokine activity
- DNA binding
- G-protein coupled receptor activity
- Growth factor activity
- GTPase activity
- Heat shock protein activity
- Kinase activity
- Lipid kinase activity
- Oxidoreductase activity
- Peroxidase activity
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor binding
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- Signal transducer activity
- Structural constituent of cytoskeleton
- Transcription factor activity
- Transcription regulator activity
- Translation regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity

Identified targets are categorized into 21 different primary and alternate sub-cellular localizations:
- Centrosome
- Chromosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Golgi apparatus
- Golgi membrane
- Lysosome
- Microtubule
- Mitochondrion
- Nuclear membrane
- Nucleolus
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Plasma membrane
- Secreted

Note: You are able to find and sort drugs according to target gene name, molecular function of target, and target localization from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 160 protein expression profiles of 97 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG and NetPath.
- BioCarta# 191 Pathways
- KEGG# 83 Pathways
- NetPath# 25 Signaling Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.


The Drug Profiles: Progress analysis and review of drug development.

RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012 provides you with a profile for each identified drug. A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms.
Principal Investigator & Partners Presentation of principal investigator and partners.
Target and Molecular Function of Target Described target(s) is/are presented with:
Official Gene Symbol – Official Gene Name [Species/Homo Sapiens] – Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight.
Patent Data Available patent information related to the drug is presented here.
Analysis Business & Markets
Collaborations and deals
Approvals and submissions
Analyst comments
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Preclinical Data Available preclinical development data, developmental history and scientific data.
Licensing Information Availability for licensing.


About the unique Drug Pipeline Update Software Application

After purchase, the Drug Pipeline Update is delivered to you via electronic download in a powerful yet easy to use desktop application which requires no installation.

Find and sort drugs by twelve different parameters plus free text search field. Our dynamic report generator lets you easily and quickly generate HTML drug profile reports directly in your web browser, whether it is a single drug profile or your own report selection of drugs that match your criteria.


Application Features Use 13 different parameters, available in drop-down menus, to find and sort among drugs
- Drug status
- Clinical Trial Status
- Principle Investigator
- Partners
- Indication
- Developmental Stage
- Compound Type
- Mechanism
- Target
- Molecular Function of Target
- Target Localization
- Targeted Pathways
- Free text search of entire drug profile contents

Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, and NetPath
- Direct links to company web pages of principal investigators

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer), whether it is a single drug profile or an entire search you want have a report of.
System Requirements - Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request free sample pages from RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012

Other selected research from the 'Drugs' category:


RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 164 companies plus partners who are today developing 192 RANKL pathway targeting drugs in 643 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 104 drugs where development has been ceased. Learn More


IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 187 companies plus partners who are today developing 245 IL-2 pathway targeting drugs in 698 developmental projects in cancer across 127 different targets. In addition, there are 4 suspended drugs and another 104 drugs where development has been ceased. Learn More

Other selected research from the 'Drug Pipeline Updates' category:


Notch Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 149 companies plus partners who are today developing 152 Notch pathway targeting drugs in 481 developmental projects in cancer across 116 different targets. In addition, there are 2 suspended drugs and another 101 drugs where development has been ceased. Learn More


Ovarian Cancer Drug Pipeline Update 2012
BioSeeker Group have identified 212 companies plus partners who are today developing 286 drugs targeting ovarian cancer in development. across 196 different targets. In addition, there are 7 suspended drugs and another 83 drugs where development has been ceased. Learn More

Other selected research from the 'R&D' category:


Analytical Tool - Apoptosis in Oncology
In this Analytical Tool, BioSeeker Group brings light and understanding of the whole industrial endeavor in apoptosis as cancer therapeutic mechanism. Learn More


Vascular Targeting Agents: Emerging Competitors
An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Lung Cancer and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Lung Cancer and Prostate Cancer. Learn More


TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 237 companies plus partners who are today developing 288 TGF-beta receptor pathway targeting drugs in 815 developmental projects in cancer across 165 different targets. In addition, there are 2 suspended drugs and another 172 drugs where development has been ceased. Learn More